Cell & Gene Therapy coverage on Pharmaceutical ... Healthcare products Regulatory Agency (MHRA) to treat CLL and marginal zone lymphoma (MZL). Patients living with the disease have limited ...

The FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) patients who have received two prior therapies. MZL is an ...

Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a ...

White blood cells, called T and B lymphocytes (B and ... slowly (described as 'indolent'), for example follicular lymphoma and marginal zone lymphoma. Others are faster growing ('aggressive ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology. Cutaneous T ...

My work focuses on the development of novel therapies for patients with B cell lymphoma, including indolent lymphomas (follicular, marginal zone, small lymphocytic), Waldenström’s macroglobulinemia, ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

The study evaluated Yescarta in patients with relapsed/refractory non-NHL, including follicular lymphoma or marginal zone lymphoma ... certain patients with B-cell lymphoma and follicular lymphoma.

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.